These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16515371)

  • 1. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature.
    Stephens JM; Botteman MF; Hay JW
    J Manag Care Pharm; 2006 Mar; 12(2):130-42. PubMed ID: 16515371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
    Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
    J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
    Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
    J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
    Cooke CE; Lee HY; Tong YP; Haines ST
    Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.
    Balkrishnan R; Rajagopalan R; Camacho FT; Huston SA; Murray FT; Anderson RT
    Clin Ther; 2003 Nov; 25(11):2958-71. PubMed ID: 14693318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
    Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
    J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan.
    King J; McAdam-Marx C; McCaleb R; Davis D; Bemberg GB; Johnson JT
    J Manag Care Spec Pharm; 2019 Jun; 25(6):646-651. PubMed ID: 31134855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
    Rascati KL; Worley K; Meah Y; Everhart D
    J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New concepts in diabetes: how multihormonal regulation can improve glycemic control.
    Blonde L; Baker DE; Davis SN; Ratner RE
    J Manag Care Pharm; 2004 Dec; 10(6 Suppl B):S3-8; quiz S9, S11-2. PubMed ID: 23570175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization.
    Aagren M; Luo W; Moës E
    J Med Econ; 2010 Mar; 13(1):16-22. PubMed ID: 19958212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
    Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
    J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data.
    McAdam-Marx C; Bellows BK; Unni S; Wygant G; Mukherjee J; Ye X; Brixner DI
    J Manag Care Spec Pharm; 2014 Jul; 20(7):691-700. PubMed ID: 24967522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a program to improve diabetes care through intensified care management activities and diabetes medication copayment reduction.
    Kogut SJ; Johnson S; Higgins T; Quilliam B
    J Manag Care Pharm; 2012 May; 18(4):297-310. PubMed ID: 22548690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Descriptive analysis of mail interventions with physicians and patients to improve adherence with antihypertensive and antidiabetic medications in a mixed-model managed care organization of commercial and Medicare members.
    Jing S; Naliboff A; Kaufman MB; Choy M
    J Manag Care Pharm; 2011 Jun; 17(5):355-66. PubMed ID: 21657805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.